Egalet Corp. Appoints Robert Roche to Board of Directors

12/8/16

Egalet Corporation (Nasdaq: EGLT), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced the appointment of Robert P. Roche, Jr. to its board of directors.

"Bob's years of commercial experience will be important as we prepare for the commercial launch of our first product developed using our proprietary Guardian Technology," said Bob Radie, president and chief executive officer. "Specifically his work in the pain space at Cephalon will be valuable as we focus on developing and commercializing innovative pain treatments."

Over the past six years, Mr. Roche has used his decades of commercial and marketing experience as the founding member of Robert Roche Associates LLC, a consulting firm that provides guidance to the pharmaceutical and healthcare industries. Prior to that Mr. Roche led commercial operations at Cephalon Inc. for fifteen years, and held the position of executive vice president starting in 2005, growing the company's revenues to over $2.4 billion in eleven years.

"Given that there are few causes more important than treating chronic pain and decreasing potential prescription opioid abuse, I am thrilled to be a part of Egalet's important mission," said Bob Roche.

Before joining Cephalon Mr. Roche served as director and vice president of worldwide strategic product development for SmithKline Beecham's central nervous system and gastrointestinal products business, where he grew their product revenues over 75 percent to $750 million. He was also managing director of SmithKline's pharmaceutical operations in the Philippines. Prior to that he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline & French as a U.S. pharmaceutical sales representative. Mr. Roche earned his MBA from the University of Pennsylvania's Wharton School of Business, and his BA from Colgate University.

Mr. Roche is a member of the board of directors of Aratana Therapeutics, Antares Pharma, Paragon Bioservices, Inc. and Bryn Mawr Hospital.

About Egalet

Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has two approved products: OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using its proprietary Guardian™ Technology, Egalet is developing a pipeline of clinical-stage, product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO™ ER, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, including the boxed warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.